Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma - 24/02/16
, David W. Chesla, P.A., A.S.C.P. c, Mathew H. Chung, M.D., F.A.C.S. a, b, dAbstract |
Background |
Genomic sequencing technology may identify personalized treatment options for patients with pancreatic adenocarcinoma.
Methods |
The study was conducted using tissue specimens obtained from 2012 to 2014. Patients with resected pancreatic adenocarcinoma were identified. Next-generation sequencing was performed from paraffin-tumor blocks. Mutational profiles were reviewed to determine available targeted therapies and clinical trial eligibility.
Results |
Thirty patients were identified. The incidence of mutations was: Kirsten rat sarcoma viral oncogene homolong (KRAS) = 87%, tumor protein 53 (TP53) = 63%, cyclin-dependent kinase inhibitor 2A (CDKN2A) = 20%, Mothers Against Decapentaplegic Homolog 4 (SMAD4) = 20%, epidermal growth factor receptor (EGFR) = 7%. Multiple mutations were found in 73%. All CDKN2A mutations occurred in male patients (P = .06), and there was a trend toward younger patient age in this group (P = .13). Potential for Federal Drug Administration (FDA)-approved targeted therapies was identified in 8 of 30 (27%). In addition, 29 of 30 (97%) had mutations applicable for ongoing phase I or II clinical trials.
Conclusions |
Next-generation sequencing of resected pancreatic adenocarcinoma specimens can determine common genetic mutations and identify patients who may be eligible for off-label use of targeted therapies or clinical trial enrollment.
Le texte complet de cet article est disponible en PDF.Keywords : Pancreatic cancer, Genetic mutations, Pancreas, KRAS, TP53
Plan
| The study was funded by a private grant from the Spectrum Health Foundation Ferguson Digestive Disease Institute (DDI.FY15.03). |
Vol 211 - N° 3
P. 506-511 - mars 2016 Retour au numéro
Article précédent
- 2015 William Hunter Harridge lecture: how did we go from operating on nearly all injured kidneys to operating on almost none of them?
- Richard A. Santucci
- Intraductal papillary mucinous neoplasm of the pancreas, one manifestation of a more systemic disease?
- Alexandra M. Roch, Carlo Maria Rosati, Jessica L. Cioffi, Eugene P. Ceppa, John M. DeWitt, Mohammad A. Al-Haddad, Michael G. House, Nicholas J. Zyromski, Attila Nakeeb, C. Max Schmidt
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?